keyboard_arrow_up

Global Fabry Disease Market to Grow at 18.08% CAGR by 2018

Global Fabry Disease Market 2015-2019 is the latest addition to Sandlerresearch.org industry research reports collection.

Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal. Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males. The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.

Analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.

Single User License of the report is Available at US $2500

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.

Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Order a copy of this report at (Prices start at US $2500 for a single user PDF) http://www.sandlerresearch.org/purchase?rname=27073 .

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Genzyme
  • Shire

Other Prominent Vendors

  • Amicus Therapeutics
  • Green Cross Corporation
  • ISU Abxis
  • JCR Pharmaceuticals
  • Protalix Biotherapeutics

Market Driver

  • Special Provisions for Orphan Drugs

Market Challenge

  • Limited Patient Population

Market Trend

  • Regulatory Assistance in Emerging Countries

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Have any Query on the Report get your Queries Resolved at http://www.sandlerresearch.org/inquire-before-buying?rname=27073 .

About US:

Sandlerresearch.org (http://www.sandlerresearch.org) is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.